Abstract
Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder caused by a CAG repeat expansion that lengthens a glutamine segment in the novel huntingtin protein. To elucidate the molecular basis of HD, we extended the polyglutamine tract of the mouse homologue, Hdh, by targetted introduction of an expanded human HD CAG repeat, creating mutant HdhneoQ50 and HdhQ50 alleles that express reduced and wild-type levels of altered huntingtin, respectively. Mice homozygous for reduced levels displayed characteristic aberrant brain development and perinatal lethality, indicating a critical function for Hdh in neurogenesis. However, mice with normal levels of mutant huntingtin did not display these abnormalities, indicating that the expanded CAG repeat does not eliminate or detectably impair huntingtin's neurogenic function. Thus, the HD defect in man does not mimic complete or partial Hdh inactivation and appears to cause neurodegenerative disease by a gain-of-function mechanism.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Martin, J.B. & Gusella, J.F. Huntington's disease: pathogenesis and management. N. Engl. J. Med. 315, 1267–1276 (1986).
Vonsattel, J.P. et al. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neuml. 44, 559–577 (1985).
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72, 971–983 (1993).
McNeil, S.M. et al. Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 6, 775–779 (1997).
Rubinsztein, D.C. et al. Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Am. J. Hum. Genet. 59, 16–22 (1996).
Gusella, J.F., Persichetti, F. & MacDonald, M.E. The genetic defect causing Huntington's disease: repeated in other contexts. Mol. Med. 3, 238–246 (1997).
Ide, K. et al. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem. Biophys. Res. Commun. 209, 1119–1125 (1995).
Trottier, Y. et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nature Genet. 10, 104–110 (1995).
Jou, Y.S. & Myers, R.M. Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Hum. Mol. Genet. 4, 465–469 (1995).
Sharp, A.H. et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14, 1065–1074 (1995).
DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron. 14, 1075–1081 (1995).
Gutekunst, C.-A. et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA. 92, 8710–8714 (1995).
Persichetti, F. et al. Normal and expanded Huntington's disease alleles produce distinguishable proteins due to translation across the CAG repeat. Mol. Med. 1, 374–383 (1995).
Trottier, Y. et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature. 378, 403–406 (1995).
Persichetti, F. et al. Huntington's disease CAG trinucleotide repeats in neuropathologically confirmed post-mortem brains. Neurobiol. Dis. 1, 159–166 (1995).
Li, X.J. et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature. 378, 398–402 (1995).
Bao, J. et al. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. USA. 93, 5037–5042 (1996).
Burke, J.R. et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med. 2, 347–350 (1996).
Kalchman, M.A. et al. HIP1, a human homologue of S cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genet. 16, 44–53 (1997).
Wanker, E.E. et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6, 487–495 (1997).
Ambrose, C.M. et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell Mol. Genet. 20, 27–38 (1994).
Duyao, M.P. et al. Homozygous inactivation of the mouse Hdh gene does not produce a Huntington's disease-like phenotype. Science. 269, 407–410 (1995).
Zeitlin, S. et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nature Genet. 11, 155–162 (1995).
Myers, R.H. et al. Homozygote for Huntington's disease. Am. J. Hum. Genet. 45, 615–618 (1989).
Wexler, N.S. et al. Homozygotes for Huntington's disease. Nature. 326, 194–197 (1987).
Nasir, J. et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 81, 811–823 (1995).
MacDonald, M.E. & Gusella, J.F. Huntington's disease: translating a CAG repeat into a pathogenic mechanism. Curr. Opin. Neurobiol. 6, 638–650 (1996).
Barnes, G.T. et al. Mouse Huntington's disease gene homolog (Hdh). Somat. Cell Mol. Genet. 20, 87–97 (1994).
Lin, B. et al. Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat [published erratum appears in Hum. Mol. Genet. 3, 530 (1994)]. Hum. Mol. Genet. 3, 85–92 (1994).
MacDonald, M.E. et al. Targeted inactivation of the mouse Huntington disease homologue Hdh . Cold Spring Harbor Symp Quant. Biol. 61, 627–638 (1996).
Lin, B. et al. Structural analysis of the 5′ region of mouse and human Huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics. 25, 707–715 (1995).
Stumpo, D.J. et al. MARCKS deficiency in mice leads to abnormal brain development and perinatal death. Proc. Natl. Acad. Sci. USA. 92, 944–948 (1995).
Wu, M. et al. Neural tube defects and abnormal brain development in F52-deficient mice. Proc. Natl. Acad. Sci. USA. 93, 2110–2115 (1996).
Hui, C.-C. & Joyner,, A.L A mouse model of Greig cephalo-polysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the GH3 gene. Nature Genet. 3, 241–246 (1993).
Shah, V. et al. A subset of p53-deficient embryos exhibit exencephaly. Nature Genet. 10, 175–180 (1995).
Kuida, K. et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature. 384, 368–372 (1996).
Gusella, J.F., Persichetti, F. & MacDonald, M.E. The genetic defect causing Huntington's disease: repeated in other contexts. Mol. Med. 3, 238–246 (1997).
Bingham, P.M. et al. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice [published erratum appears in. Nature Genet. 9, 191–196 (1995).
Goldberg, Y.P. et al. Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. Hum. Mol. Genet. 5, 177–185 (1996).
Ikeda, H. et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo . Nature Genet. 13, 196–202 (1996).
Burright, E.N. et al. SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 82, 937–948 (1995).
Mangiarini, L.E. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87, 493–506 (1996).
Hanks, M. et al. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2 . Science. 269, 679–682 (1995).
Warner, J.P., Barren, L.H. & Brock, D.J. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol. Cell. Probes. 7, 235–239 (1993).
Nagy, A. et al. Derivation of completely cell culture–derived mice from early-passage embryonic stem cells. Proc Natl. Acad. Sci. USA. 90, 8424–8428 (1993).
Wurst, W. & Joyner, A.L. Production of targeted embryonic stem cell clones in Gene Targeting: A Practical Approach (ed. A.L. Joyner) 33–62 (Oxford University Press, Oxford, UK, 1993).
Nagy, A. & Rossant, J. Production of completely ES cell-derived fetuses. in Gene Targeting: A Practical Approach (ed. A.L. Joyner) 147–180 (Oxford University Press, Oxford, UK, 1993).
Miller, M.W. & Nowakowski, R.S. Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system. Brain Res. 457, 44–52 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
White, J., Auerbach, W., Duyao, M. et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 17, 404–410 (1997). https://doi.org/10.1038/ng1297-404
Issue Date:
DOI: https://doi.org/10.1038/ng1297-404
This article is cited by
-
Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome
Cell Death & Disease (2023)
-
Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity
Nature Communications (2023)
-
The evolutionary history of the polyQ tract in huntingtin sheds light on its functional pro-neural activities
Cell Death & Differentiation (2022)
-
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
BioDrugs (2022)
-
Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease
Nature Communications (2021)